Tan, C. R., Derkach, A., Nemirovsky, D., Ciardiello, A., Diamond, B., Hultcrantz, M., . . . Korde, N. (2023). Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood cancer journal (New York), 13(1), 112-8. https://doi.org/10.1038/s41408-023-00882-y
Chicago-Zitierstil (17. Ausg.)Tan, Carlyn Rose, et al. "Bortezomib, Lenalidomide and Dexamethasone (VRd) Vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal (New York) 13, no. 1 (2023): 112-8. https://doi.org/10.1038/s41408-023-00882-y.
MLA-Zitierstil (9. Ausg.)Tan, Carlyn Rose, et al. "Bortezomib, Lenalidomide and Dexamethasone (VRd) Vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal (New York), vol. 13, no. 1, 2023, pp. 112-8, https://doi.org/10.1038/s41408-023-00882-y.